Maxicold tablets, instructions for use

Be sure to read these instructions for use of MAXICOLD® tablets and consult a specialist before taking this drug.

Registration number: LP-000077

Trade name of the drug: Maxicold®

International nonproprietary or generic name: Paracetamol + Phenylephrine + [Ascorbic acid]

Dosage form: film-coated tablets

Composition per tablet

Active ingredients: paracetamol - 500 mg, phenylephrine hydrochloride - 10 mg, ascorbic acid - 30 mg.

Excipients: core: croscarmellose sodium - 28.00 mg, calcium hydrogen phosphate - 82.62 mg, ethylcellulose - 0.20 mg, hyprolose (hydroxypropylcellulose) - 35.00 mg, magnesium stearate - 7.00 mg, talc - 7, 00 mg, sunset yellow dye (E 110) - 0.18 mg; shell: hypromellose (hydroxypropyl methylcellulose) - 13.200 mg, hyprolose (hydroxypropylcellulose) - 7.701 mg, talc - 6.300 mg, titanium dioxide - 2.750 mg, sunset yellow dye (E 110) - 0.049 mg or OPADRAY 20A230018 Orange (OPADRY 20А230018 Orange ) - 30.00 mg [Hypromellose (hydroxypropylmethylcellulose) - 13.200 mg, hyprolose (hydroxypropylcellulose) - 7.701 mg, talc - 6.300 mg, titanium dioxide - 2.750 mg, sunset yellow dye (E 110) - 0.049 mg].

Pharmacological properties

The combined drug has an antipyretic and analgesic effect, intended to relieve the symptoms of colds and flu.

The effect of the drug is due to the properties of its constituent components.

Paracetamol is a non-narcotic analgesic, has an antipyretic and analgesic effect due to the blockade of cyclooxygenase in the central nervous system and its effect on the centers of pain and thermoregulation. Reduces headaches, muscle pain, and fever.

Phenylephrine is an alpha1-adrenergic stimulant that has little effect on beta-adrenergic receptors of the heart; is not a catecholamine. Causes a narrowing of arterioles, thereby reducing swelling and hyperemia of the nasal mucosa, making breathing through the nose easier.

Ascorbic acid – increases the body’s resistance to infections, replenishes the increased need for vitamin C during colds and flu.

Buy Maxicold Rhino powder for preparing a solution for oral administration Raspberry 15g No. 10 in pharmacies

Instructions for use Maxicold Buy at the pharmacy Maxicold Rino por. d/r-ra internal Raspberry 15g No. 10 Dosage forms powder for injection. oral solution raspberry 15g

Synonyms GrippoFlu for colds and flu GrippoFlu Extra for colds and flu Stopgripan Stopgripan forte TeraFlu for flu and colds Group Combinations of paracetamol and adrenergic stimulants International nonproprietary name Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid Composition Active substances: paracetamol 325 mg, pheniramine maleate 20 mg, phenylephrine hydrochloride 10 mg, ascorbic acid 50 mg. Manufacturers Pharmstandard-Leksredstva OJSC (Russia) Pharmacological action A combined drug that has antipyretic, vasoconstrictor, analgesic and antiallergic effects. Paracetamol has an antipyretic and analgesic effect: it reduces the pain syndrome observed with “colds” - sore throat, headache, muscle and joint pain, and reduces high fever. Pheniramine has an antiallergic effect: eliminates swelling and hyperemia of the mucous membranes of the nasal cavity, nasopharynx and paranasal sinuses, reduces runny nose and lacrimation. Phenylephrine has a vasoconstrictor effect: it reduces swelling of the nasopharyngeal mucosa. Ascorbic acid (vitamin C) replenishes the increased need for vitamin C during colds and flu, especially in the initial stages of the disease; increases the body's resistance to infectious diseases. The combined action of pheniramine and phenylephrine leads to a reduction in nasal congestion and a significant improvement in nasal breathing. Side effects Possible allergic reactions, drowsiness, nausea, epigastric pain, dry mouth, accommodation paresis, increased excitability, dizziness, increased blood pressure, difficulty falling asleep, urinary retention, rarely: anemia. Indications for use Symptomatic treatment of “colds”, ARVI, flu, accompanied by high fever, chills, headache, runny nose, pain in the sinuses and throat, nasal congestion, sneezing and pain in muscles and joints. Contraindications Hypersensitivity to individual components of the drug, severe liver/renal failure, pregnancy, breastfeeding, children (up to 12 years). Prescribe with caution for: arterial hypertension, diabetes mellitus, closed-angle glaucoma, liver or kidney diseases, prostate hyperplasia, glucose-6-phosphate dehydrogenase deficiency. Directions for use and dosage : Dissolve the contents of one packet in 1 glass of boiled hot water. Serve hot. You can add sugar to taste. A repeat dose can be taken every 4 hours (no more than 3 doses in 24 hours). The drug can be used at any time of the day, but the best effect comes from taking the drug before bed, at night. If there is no relief of symptoms within 3 days after starting to take the drug, you should consult a doctor. Overdose Symptoms: nausea, vomiting, pain in the epigastric region; hepatotoxic and nephrotoxic effects; in severe cases, liver failure, encephalopathy and coma develop. Treatment: you should do a gastric lavage, take activated charcoal and consult a doctor. Interaction It is recommended to refrain from taking the drug when taking monoamine oxidase inhibitors. The risk of hepatotoxic action of paracetamol increases with the simultaneous administration of barbiturates, diphenine, carbamazepine, rifampicin, zidovudine and other inducers of microsomal liver enzymes. Antidepressants, antiparkinsonian and antipsychotic drugs, phenothiazine derivatives increase the risk of developing urinary retention, dry mouth, and constipation. Reduces the hypotensive effect of guanethidine, which in turn enhances the alpha-adrenergic stimulating activity of phenylephrine. Special instructions To avoid toxic liver damage, paracetamol should not be combined with alcoholic beverages, or taken by persons prone to chronic alcohol consumption. The risk of developing liver damage increases in patients with alcoholic hepatosis. If the drug is taken by patients suffering from diabetes or on a low-sugar diet, it should be taken into account that each sachet contains 13 g of sugar, which corresponds to 1.0 XE. During treatment, it is not recommended to drive a car or other machinery that requires concentration and high speed of psychomotor reactions. Do not use the drug from damaged sachets. Storage conditions Store out of reach of children, in a dry place, protected from light, at a temperature not exceeding 30 C.

Pharmacokinetics

Paracetamol: well absorbed in the intestine, time to reach maximum concentration (Tmax) is 0.5-2 hours; connection with plasma proteins – 15%. Metabolized in the liver to form both active and inactive metabolites. The half-life (T1/2) is 1-4 hours. It is mainly excreted by the kidneys in the form of metabolites - glucuronides and sulfates, 3% - unchanged.

Phenylephrine: After oral administration, phenylephrine is poorly absorbed from the gastrointestinal (GI) tract. Metabolized with the participation of monoamine oxidase (MAO) in the intestinal wall and during the “first pass” through the liver. The bioavailability of phenylephrine is low.

Ascorbic acid: Absorbed in the gastrointestinal tract (mainly in the jejunum). Tmax after oral administration – 4 hours. Easily penetrates into leukocytes, platelets, and then into all tissues; the highest concentration is achieved in the glandular organs, leukocytes, liver and lens of the eye; penetrates the placenta. Metabolized primarily in the liver into deoxyascorbic acid and further into oxaloacetic acid and ascorbate-2-sulfate. It is excreted by the kidneys, through the intestines, with sweat, breast milk unchanged and in the form of metabolites.

Contraindications

Hypersensitivity to any component of the drug; severe renal/liver failure; hyperthyroidism (including thyrotoxicosis); heart disease (severe stenosis of the aortic mouth, acute myocardial infarction, tachyarrhythmias); arterial hypertension; simultaneous use of tricyclic antidepressants, beta-blockers, monoamine oxidase inhibitors, incl. within 14 days after cancellation; simultaneous use of other paracetamol-containing drugs and drugs to relieve symptoms of colds, flu and nasal congestion; prostatic hyperplasia; angle-closure glaucoma; children's age (up to 9 years, as well as children weighing less than 30 kg).

Maxicold Rino powder for preparing raspberry solution 15g N 10

Latin name

MAXICOLD RINO

Release form

Maxicold Rhino. Powder for preparing a solution for oral administration (raspberry) from light pink to dark pink with a reddish tint, crystalline, with a specific odor; the presence of white crystals and easily crumbling lumps is allowed; the powder dissolves in 250 ml of hot water to form an opalescent pink solution with a characteristic raspberry odor.

pharmachologic effect

The combined drug has antipyretic, vasoconstrictor, analgesic and antiallergic effects.

Paracetamol

It has an antipyretic and analgesic effect: it reduces the pain syndrome observed with “colds” - sore throat, headache, muscle and joint pain, and reduces high temperature.

Pheniramine

Has an antiallergic effect: eliminates swelling and hyperemia of the mucous membranes of the nasal cavity, nasopharynx and paranasal sinuses, reduces runny nose and lacrimation.

Phenylephrine

Has a vasoconstrictor effect: reduces swelling of the nasopharyngeal mucosa.

Ascorbic acid (vitamin C)

Replenishes the increased need for vitamin C during colds and flu, especially in the initial stages of the disease; increases the body's resistance to infectious diseases. The combined action of pheniramine and phenylephrine leads to a reduction in nasal congestion and a significant improvement in nasal breathing.

Indications

Symptomatic treatment of “colds”, ARVI, flu, accompanied by high fever, chills, headache, runny nose, pain in the sinuses and throat, nasal congestion, sneezing and pain in muscles and joints.

Contraindications

Hypersensitivity to individual components of the drug.
Severe renal/liver failure.
Pregnancy.
Breastfeeding period.
Children's age (up to 12 years).

With caution when:

Arterial hypertension.
Diabetes mellitus.
Angle-closure glaucoma.
Liver or kidney diseases.
Prostatic hyperplasia.
Glucose-6-phosphate dehydrogenase deficiency.

Use during pregnancy and breastfeeding

Contraindicated during pregnancy and breastfeeding.

special instructions

To avoid toxic liver damage, paracetamol should not be combined with alcoholic beverages, or taken by persons prone to chronic alcohol consumption. The risk of developing liver damage increases in patients with alcoholic hepatosis.

If the drug is taken by patients suffering from diabetes or on a low-sugar diet, it should be taken into account that each sachet contains 13 g of sugar, which corresponds to 1.0 XE.

Impact on the ability to drive vehicles and operate machinery

During treatment, it is not recommended to drive a car or other machinery that requires concentration and high speed of psychomotor reactions. Do not use the drug from damaged sachets.

Compound

1 sachet contains:

Active ingredients

Paracetamol 325 mg.
Pheniramine maleate 20 mg.
Phenylephrine hydrochloride 10 mg.
Ascorbic acid 50 mg.

Excipients: citric acid monohydrate, malic acid, sucrose (refined sugar), titanium dioxide, sodium citrate dihydrate, raspberry flavor, quinoline yellow dye, acid red dye (azorubine), calcium hydrogen phosphate dihydrate (tricalcium phosphate tribasic), ethylcellulose.

Directions for use and doses

Dissolve the contents of one packet in 1 glass of boiled hot water. Serve hot. You can add sugar to taste.

A repeat dose can be taken every 4 hours (no more than 3 doses in 24 hours). Maxicold Rhino for colds and flu can be used at any time of the day, but the best effect comes from taking the drug before bed, at night. If there is no relief of symptoms within 3 days after starting to take the drug, you should consult a doctor.

Side effects

Maybe:

Allergic reactions, drowsiness, nausea, epigastric pain, dry mouth, accommodation paresis, increased excitability, dizziness, increased blood pressure, difficulty falling asleep, urinary retention.

Rarely:

Anemia

Drug interactions

It is recommended to refrain from taking the drug when taking monoamine oxidase inhibitors.

The risk of hepatotoxic action of paracetamol increases with the simultaneous administration of barbiturates, diphenine, carbamazepine, rifampicin, zidovudine and other inducers of microsomal liver enzymes.

Antidepressants, antiparkinsonian and antipsychotic drugs, phenothiazine derivatives increase the risk of developing urinary retention, dry mouth, and constipation.

Reduces the hypotensive effect of guanethidine, which in turn enhances the alpha-adrenergic stimulating activity of phenylephrine.

Overdose

Symptoms: nausea, vomiting, pain in the epigastric region; hepatotoxic and nephrotoxic effects; in severe cases, liver failure, encephalopathy and coma develop.

Treatment: you should do a gastric lavage, take activated charcoal and consult a doctor.

Storage conditions

Store in a dry place, protected from light, out of reach of children, at a temperature not exceeding 30°C.

Best before date

2 years.

Directions for use and doses

Orally, before meals or 1-2 hours after meals, with plenty of liquid.

Adults and children over 12 years of age (body weight over 40 kg): 1-2 tablets every 4-6 hours. The frequency of administration is no more than 4 times a day with an interval of at least 4 hours.

Children aged 9 to 12 years (body weight more than 30 kg): 1 tablet every 4-6 hours. The frequency of administration is no more than 4 times a day with an interval of at least 4 hours.

The drug is not recommended for use for more than 5 days as an analgesic and 3 days as an antipyretic without consulting a doctor. If symptoms persist, you should consult a doctor.

DO NOT EXCEED THE SPECIFIED DOSE.

Side effect

Allergic reactions are possible (skin rash, skin hyperemia, urticaria, angioedema).

Paracetamol: hematopoietic disorders (anemia, thrombocytopenia, methemoglobinemia). Phenylephrine: headache, nausea or vomiting; angina pectoris, bradycardia, shortness of breath, increased or decreased blood pressure, palpitations, tachycardia, ventricular arrhythmia (especially when used in high doses), irritability, restlessness, allergic reactions.

Ascorbic acid: can cause irritation of the gastrointestinal mucosa; with prolonged use of large doses - nausea, vomiting, diarrhea, hyperacid gastritis, ulceration of the gastrointestinal mucosa; decreased capillary permeability (possible deterioration of tissue trophism, increased blood pressure, hypercoagulation, development of microangiopathies). Thrombocytosis, hyperprothrombinemia, erythropenia, neutrophilic leukocytosis, hypokalemia, glycosuria, and inhibition of the function of the pancreatic insular apparatus are also possible.

With long-term use in doses significantly higher than recommended, the likelihood of renal dysfunction increases (moderate pollakiuria, hyperoxaluria, nephrolithiasis, damage to the glomerular apparatus of the kidneys), increased excitability of the central nervous system, headache, insomnia. If any unwanted reactions occur, consult your doctor.

Overdose

In case of overdose, seek medical attention immediately, even if you feel well, as there is a risk of delayed signs of serious liver damage.

In case of overdose, symptoms are usually caused by exposure to high doses of paracetamol.

Symptoms: during the first 24 hours after administration - pallor of the skin, nausea, vomiting, anorexia, abdominal pain; impaired glucose metabolism, metabolic acidosis. Symptoms of liver dysfunction may appear 12-48 hours after an overdose. In case of severe overdose - liver failure with progressive encephalopathy, coma, death; acute renal failure with tubular necrosis (including in the absence of severe liver damage); arrhythmia, pancreatitis. The hepatotoxic effect in adults occurs when taking 10 g or more.

Treatment: administration of SH-group donors and precursors for the synthesis of glutathione - methionine within 8-9 hours after an overdose and acetylcysteine - within 8 hours. The need for additional therapeutic measures (further administration of methionine, intravenous administration of acetylcysteine) is determined depending on the the concentration of paracetamol in the blood, as well as the time elapsed after its administration.

Maxicold Rhino por d/r-ra vn prime raspberry 15 g pack comb/pack cards x10

Trade name: Maxicold Rino (Maxycold Rino) International name: Paracetamol+Phenylephrine+Pheniramine+[Ascorbic acid]& (Paracetamol+Phenylephrine+Pheniramine+Ascorbic acid) Pharmacological group: acute respiratory infections and “colds” symptoms remedy (analgesic non-narcotic drug + alpha - adrenergic agonist + H1-histamine receptor blocker + vitamin) Pharmacological group for ATC: N02BE51. Paracetamol in combination with other drugs (excluding psychotropic drugs) Pharmacological action: alpha- and beta-adrenergic stimulant, antihistamine, vasoconstrictor, antipyretic, cold and flu-eliminating symptoms Pharmacodynamics: Combined drug. Paracetamol is a non-narcotic analgesic, acting on the centers of pain and thermoregulation, and has an analgesic and antipyretic effect. Pheniramine is a blocker of H1-histamine receptors, reduces rhinorrhea and lacrimation, eliminates spastic phenomena. Phenylephrine is an adrenergic agonist with a moderate vasoconstrictor effect (stimulation of alpha1-adrenergic receptors). Ascorbic acid is involved in the regulation of redox processes, carbohydrate metabolism, blood clotting, tissue regeneration, in the synthesis of steroid hormones, increases the body's resistance to infections, reduces vascular permeability, reduces the need for vitamins B1, B2, A, E, folic acid, pantothenic acid. Improves the tolerability of paracetamol and prolongs its effect (associated with prolongation of T1/2). Indications for use: Feverish syndrome (colds and infectious diseases). Pain syndrome (mild and moderate severity): arthralgia, myalgia, neuralgia, migraine, toothache and headache, algomenorrhea. Sinusitis, rhinorrhea (acute rhinitis, allergic rhinitis). Contraindications: Hypersensitivity, portal hypertension, alcoholism, glucose-6-phosphate dehydrogenase deficiency, renal failure,

pregnancy (I and III trimesters), lactation period. Dosage regimen: Orally, 1 packet dissolved in 200 ml of water, 4 times a day. Side effects: Allergic reactions (skin rash, itching, urticaria, angioedema), nausea, epigastric pain, anemia, thrombocytopenia, agranulocytosis. Increased excitability, dizziness, increased blood pressure, difficulty falling asleep. Mydriasis, accommodation paresis, increased intraocular pressure, dry mouth, urinary retention. With long-term use in large doses - hepatotoxic effect, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia, nephrotoxicity (renal colic, glycosuria, interstitial nephritis, papillary necrosis).

Overdose Symptoms (caused by paracetamol): pallor of the skin, loss of appetite, nausea, vomiting, hepatonecrosis (the severity of necrosis due to intoxication directly depends on the degree of overdose). Toxic effects in adults are possible after taking more than 10-15 g of paracetamol: increased activity of liver transaminases, increased prothrombin time (12-48 hours after administration), a detailed clinical picture of liver damage appears after 1-6 days. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis). Treatment: administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8-9 hours after an overdose and N-acetylcysteine after 12 hours. The need for additional therapeutic measures (further administration of methionine, intravenous administration of N-acetylcysteine) is determined depending on on the concentration of paracetamol in the blood, as well as on the time elapsed after taking it. Interaction: Enhances the effects of MAO inhibitors, sedatives, ethanol. Ethanol enhances the sedative effect of antihistamines. Antidepressants, antiparkinsonian and antipsychotic drugs, phenothiazine derivatives increase the risk of developing urinary retention, dry mouth, and constipation. GCS increase the risk of developing increased intraocular pressure. Paracetamol reduces the effectiveness of uricosuric drugs and increases the effectiveness of indirect anticoagulants. Tricyclic antidepressants enhance their sympathomimetic effect; simultaneous administration of halothane increases the risk of developing ventricular arrhythmia. Reduces the hypotensive effect of guanethidine, which in turn enhances the alpha-adrenergic stimulating activity of phenylephrine. Special instructions: During the treatment period, it is necessary to refrain from drinking ethanol (possible development of hepatotoxic effects), driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

With caution: Congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), angle-closure glaucoma, prostatic hyperplasia, childhood (up to 15 years - for a dosage form intended for adults), childhood (up to 6 years - for a pediatric dosage form).

Manufacturer: Pharmstandard-Leksredstva OJSC, Russia Registration certificate holder: Pharmstandard-Leksredstva OJSC, Russia Form of release: powder for the preparation of solution for oral administration orange, lemon, raspberry (packets of combined material) 15 g Ingredients: ascorbic acid 50 mg, paracetamol 325 mg, phenylephrine hydrochloride 10 mg, pheniramine maleate 20 mg Dispensed without a doctor's prescription Shelf life: 2 years Registration data: LSR-000054 dated 04/26/2007 Registration certificate status: valid Pharmaceutical article number: LSR-000054-260407 HS codes: 3004 50 100 9

Interaction with other drugs

The drug enhances the effects of monoamine oxidase inhibitors, sedatives, and ethanol.

The risk of developing the hepatotoxic effect of paracetamol increases with simultaneous use of ethanol, hepatotoxic drugs, inducers of microsomal oxidation enzymes in the liver (phenytoin, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants, etc.).

Concomitant use of paracetamol in high doses increases the effect of anticoagulant drugs (decreased synthesis of procoagulant factors in the liver). Paracetamol reduces the effectiveness of uricosuric drugs.

Long-term use of barbiturates reduces the effectiveness of paracetamol. Metoclopramide and domperidone increase, and cholestyramine reduces the rate of absorption of paracetamol. Inhibitors of microsomal oxidation enzymes (including cimetidine) reduce the risk of hepatotoxic action of paracetamol.

The simultaneous use of ethanol and paracetamol contributes to the development of acute pancreatitis. Long-term combined use of paracetamol and nonsteroidal anti-inflammatory drugs increases the risk of developing “analgesic” nephropathy and renal papillary necrosis, and the onset of end-stage renal failure. Simultaneous long-term administration of paracetamol in high doses and salicylates increases the risk of developing kidney or bladder cancer. Diflunisal increases the plasma concentration of paracetamol by 50%, the risk of developing hepatotoxicity. Myelotoxic drugs enhance the hematotoxicity of paracetamol.

Phenylephrine reduces the hypotensive effect of diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine), and reduces the antianginal effect of nitrates.

Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the hypertensive effect of pheniramine. Monoamine oxidase inhibitors (including furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the vasoconstrictor effect and arrhythmogenicity of phenylephrine; arterial hypertension is possible against the background of reserpine. Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect of pheniramine.

Inhalational anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias. Thyroid hormones increase (mutually) the effect of phenylephrine and the associated risk of coronary insufficiency (especially in coronary atherosclerosis).

Ascorbic acid increases the concentration of benzylpenicillin and tetracyclines in the blood, reduces the effectiveness of heparin and indirect anticoagulants, increases the overall clearance of ethanol, which in turn reduces the concentration of ascorbic acid in the body, reduces the therapeutic effect of antipsychotic drugs (neuroleptics) phenothiazine derivatives, tubular reabsorption of amphetamine and tricyclics antidepressants.

When used simultaneously with acetylsalicylic acid, the urinary excretion of ascorbic acid increases and the excretion of acetylsalicylic acid decreases. Acetylsalicylic acid, oral contraceptives, fresh juices and alkaline drinks reduce the absorption and absorption of ascorbic acid.

Ascorbic acid improves the absorption of iron preparations in the intestine; increases the risk of developing crystalluria during treatment with salicylates and short-acting sulfonamides, slows down the excretion of acids by the kidneys, increases the excretion of drugs that have an alkaline reaction (including alkaloids), reduces the concentration of oral contraceptives in the blood, and reduces the chronotropic effect of isoprenaline. With long-term use or use in high doses, it can interfere with the interaction of disulfiram and ethanol; in high doses, it increases the excretion of mexiletine by the kidneys.

Quinoline drugs, calcium chloride, salicylates, and glucocorticoids deplete ascorbic acid reserves when used for a long time. Barbiturates and primidone increase the excretion of ascorbic acid in the urine.

Maxicold®

The drug enhances the effects of monoamine oxidase inhibitors, sedatives, and ethanol.

Concomitant use of paracetamol in high doses increases the effect of anticoagulant drugs (decreased synthesis of procoagulant factors in the liver).

Paracetamol reduces the effectiveness of uricosuric drugs.

Long-term use of barbiturates reduces the effectiveness of paracetamol.

Metoclopramide and domperidone increase, and cholestyramine reduces the rate of absorption of paracetamol.

Inhibitors of microsomal oxidation enzymes (including cimetidine) reduce the risk of hepatotoxic action of paracetamol.

The simultaneous use of ethanol and paracetamol contributes to the development of acute pancreatitis.

Long-term combined use of paracetamol and nonsteroidal anti-inflammatory drugs increases the risk of developing “analgesic” nephropathy and renal papillary necrosis, and the onset of end-stage renal failure.

Simultaneous long-term administration of paracetamol in high doses and salicylates increases the risk of developing kidney or bladder cancer.

Diflunisal increases the plasma concentration of paracetamol by 50% - the risk of developing hepatotoxicity.

Myelotoxic drugs enhance the hematotoxicity of paracetamol.

Phenylephrine reduces the hypotensive effect of diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine), and reduces the antianginal effect of nitrates.

Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the hypertensive effect of pheniramine.

Monoamine oxidase inhibitors (including furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the vasoconstrictor effect and arrhythmogenicity of phenylephrine; arterial hypertension is possible against the background of reserpine.

Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect of pheniramine.

Inhalational anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias.

Thyroid hormones increase (mutually) the effect of phenylephrine and the associated risk of coronary insufficiency (especially in coronary atherosclerosis).

Ascorbic acid increases the concentration of benzylpenicillin and tetracyclines in the blood, reduces the effectiveness of heparin and indirect anticoagulants, increases the overall clearance of ethanol, which in turn reduces the concentration of ascorbic acid in the body, reduces the therapeutic effect of antipsychotic drugs (neuroleptics) - phenothiazine derivatives, tubular reabsorption of amphetamine and tricyclic antidepressants.

With long-term use or use in high doses, it can interfere with the interaction of disulfiram and ethanol; in high doses, it increases the excretion of mexiletine by the kidneys.

Quinoline drugs, calcium chloride, salicylates, and glucocorticoids deplete ascorbic acid reserves when used for a long time.

Barbiturates and primidone increase the excretion of ascorbic acid in the urine.

special instructions

Before taking the drug, consult a doctor in case of concomitant use of metoclopramide, domperidone, cholestyramine (due to the fact that metoclopramide and domperidone increase, and cholestyramine reduces the rate of absorption of paracetamol), anticoagulants (since the concomitant use of paracetamol in high doses increases the effect of anticoagulant medicines).

Taking the drug distorts the results of laboratory tests assessing the concentration of glucose and uric acid in plasma.

When using the drug for more than 5-7 days, peripheral blood counts and the functional state of the liver should be monitored.

The use of the drug during pregnancy is possible only as prescribed by a doctor.

TO AVOID TOXIC DAMAGE TO THE LIVER, THE DRUG SHOULD NOT BE COMBINED WITH ALCOHOL BEVERAGES, OR TAKEN BY PERSONS WITH CHRONIC ALCOHOLISM.

The drug does not have a negative effect on the performance of potentially hazardous activities that require special attention and quick reactions.

Maxicold, 10 pcs., film-coated tablets

The drug enhances the effects of monoamine oxidase inhibitors, sedatives, and ethanol.

Long-term use of barbiturates reduces the effectiveness of paracetamol.

Metoclopramide and domperidone

increase, and cholestyramine reduces the rate of absorption of paracetamol. Inhibitors of microsomal oxidation enzymes (including cimetidine) reduce the risk of hepatotoxic action of paracetamol.

Diflunisal

increases the plasma concentration of paracetamol by 50% - the risk of developing hepatotoxicity. Myelotoxic drugs enhance the hematotoxicity of paracetamol.

Phenylephrine

reduces the hypotensive effect of diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine), reduces the antianginal effect of nitrates.

Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics

reduce the hypertensive effect of pheniramine. Monoamine oxidase inhibitors (including furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the vasoconstrictor effect and arrhythmogenicity of phenylephrine; arterial hypertension is possible against the background of reserpine. Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect of pheniramine.

Inhalational anesthetics

(including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias.

Thyroid hormones

increase (mutually) the effect of phenylephrine and the associated risk of coronary insufficiency (especially with coronary atherosclerosis).

Ascorbic acid

increases the concentration of benzylpenicillin and tetracyclines in the blood, reduces the effectiveness of heparin and indirect anticoagulants, increases the total clearance of ethanol, which in turn reduces the concentration of ascorbic acid in the body, reduces the therapeutic effect of antipsychotic drugs (neuroleptics) - phenothiazine derivatives, tubular reabsorption of amphetamine and tricyclic antidepressants .

Ascorbic acid

improves the absorption of iron preparations in the intestines; increases the risk of developing crystalluria during treatment with salicylates and short-acting sulfonamides, slows down the excretion of acids by the kidneys, increases the excretion of drugs that have an alkaline reaction (including alkaloids), reduces the concentration of oral contraceptives in the blood, and reduces the chronotropic effect of isoprenaline. With long-term use or use in high doses, it can interfere with the interaction of disulfiram and ethanol; in high doses, it increases the excretion of mexiletine by the kidneys.